Abbott (ABT) stock fell 8% after missing Q4 earnings expectations, with nutrition sales dropping 8.9% due to lower volumes and strategic price cuts on baby formula and supplements.
Abbott to acquire Exact Sciences for $21 billion, gaining leadership in cancer screening with Cologuard and expanding its diagnostics portfolio into fast-growing oncology segment.
Abbott Laboratories is in talks to acquire Exact Sciences Corp. for ~$16B, marking its biggest healthcare deal of 2025 and largest acquisition in nearly 10 years.
